Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong

por Loong, Herbert H., Wong, Carlos K. H., Leung, Linda K. S., Tan, S. C., Jen, Jason, Lee, Mary Y. K., Aguiar-Ibáñez, Raquel, Wang, Jingshu
Publicado 2020